Lakewood-Amedex Inc
Lakewood-Amedex is dedicated to developing world-class antimicrobials with over 100 years of combined pharmaceutical industry experience. They focus on creating novel antimicrobial therapies, particularly Bisphosphocins™, to address serious infectious diseases and antibiotic resistance. Their approach involves rapidly eliminating bacterial and fungal infections directly at the site of infection using Bisphosphocins™, which depolarize microbial cell membranes within minutes. The company's mission is to improve lives by fighting challenging infections through groundbreaking innovation, aiming for first-in-class treatments that overcome bacterial resistance and treat non-bacterial infectious diseases.
Industries
Nr. of Employees
small (1-50)
Lakewood-Amedex Inc
8031 Cooper Creek Blvd., Unit 103, University Park, FL 34201
Patents
Products
Lead topical antimicrobial candidate (gel formulation)
A lead synthetic topical antimicrobial advanced into Phase 2 development for treatment of infected diabetic foot ulcers; program includes randomized, placebo‑controlled, dose‑escalation studies and microbiological endpoint assessments.
Lead topical antimicrobial candidate (gel formulation)
A lead synthetic topical antimicrobial advanced into Phase 2 development for treatment of infected diabetic foot ulcers; program includes randomized, placebo‑controlled, dose‑escalation studies and microbiological endpoint assessments.
Services
Design and execution of randomized, multi‑center, double‑blind, dose‑escalation clinical trials including safety, tolerability and microbiological endpoints.
Lead identification, in vitro and in vivo pharmacological profiling and progression of early discovery candidates through preclinical stages.
Development and optimization of topical gel formulations and other locally delivered dosage forms intended for wound, pulmonary or bladder administration.
Regulatory strategy and chemistry, manufacturing and controls (CMC) support for IND/NDA interactions, DMFs and post‑approval change protocols.
Design and execution of randomized, multi‑center, double‑blind, dose‑escalation clinical trials including safety, tolerability and microbiological endpoints.
Lead identification, in vitro and in vivo pharmacological profiling and progression of early discovery candidates through preclinical stages.
Development and optimization of topical gel formulations and other locally delivered dosage forms intended for wound, pulmonary or bladder administration.
Regulatory strategy and chemistry, manufacturing and controls (CMC) support for IND/NDA interactions, DMFs and post‑approval change protocols.
Expertise Areas
- Clinical trial management
- Topical and local antimicrobial therapy development
- Preclinical drug discovery and pharmacology
- Formulation development and local delivery
Key Technologies
- Synthetic broad‑spectrum antimicrobial chemistry
- Topical gel formulation
- Inhalation and intravesical delivery methods
- In vitro biofilm efficacy assays
News & Updates
Announcement of new board appointment on February 12, 2025.
Various scientific publications detailing the activity and efficacy of Nu-3 and Bisphosphocins™ against resistant bacteria and biofilms.
Lakewood-Amedex enrolled the first patient in a Phase 2 clinical trial for treating diabetic foot ulcers with Nu-3 gel.
Announcement of new board appointment on February 12, 2025.
Various scientific publications detailing the activity and efficacy of Nu-3 and Bisphosphocins™ against resistant bacteria and biofilms.
Lakewood-Amedex enrolled the first patient in a Phase 2 clinical trial for treating diabetic foot ulcers with Nu-3 gel.